Original Article

The Compatibility of the Treatment Modalities to the Recommendations of the Kidney Disease Outcomes Quality Initiative Guideline in Chronic Kidney Disease Patients with Diabetes

Abstract

Background: Diabetes mellitus (DM) and chronic kidney disease (CKD) are global growing health problems. Since DM is the major cause for CKD etiology, its development can be prevented with simple measures, like achievements of glycemic, lipid and blood pressure targets. This study aimed to evaluate whether the treatment goals for CKD patients with DM are achieved under the Kidney Disease Outcomes Quality Initiative (KDOQI) guideline.

Methods: Overall, 160 CKD patients with DM were enrolled in the study performed in Usak, Turkey from Jan 2016 to Jan 2018. Compatibility with treatment goals defined in KDOQI 2012 guideline for HbA1c levels, hypertension and dyslipidemia were evaluated retrospectively.

Results: Of 160 CKD patients [15 (9.4%) in stage 3a, 53 (33.1%) stage 3b, 51 (31.9%) stage 4 and 41 (25.6%) stage 5], 23 patients in stage 5 were on hemodialysis. Total compliance rate to hyperglycemia treatment was 94 of 160 patients (58.8%). Compatibility rates between different stages of CKD were similar. Hypertension was detected only in 134 patients. Sixty-six (49.3%) patients were compatible with the treatment goals, and as the CKD stages progressed, the rate of patients achieving hypertension treatment goals was declined (P=0.001). One-hundred and thirty-seven patients were not on hemodialysis and fifty-four (39.9%) of 137 patients achieved dyslipidemia goal. There was no difference between different stages of CKD.

Conclusion: Under KDOQI 2012 guideline, treatment goal for hyperglycemia was better achieved than the treatment goals for hypertension and dyslipidemia. In CKD patients with DM the physicians should be also focused on the treatment of hypertension and dyslipidemia.

1. Cho NH and Kirigia J, Mbanya JC, et al (2017), IDF Diabetes Atlas, Eight Edition. Available from: https://diabetesatlas.org/upload/resources/previous/files/8/IDF_DA_8e-EN-final.pdf
2. Onat A, Hergenc G, Uyarel H, et al (2006). Prevalence, incidence, predictors and outcome of type 2 diabetes in Turkey. Anadolu Kardiyol Derg, 6(4):314-21.
3. Hill NR, Fatoba ST, Oke JL, et al (2016). Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One, 11(7):e0158765.
4. Bailey RA, Wang Y, Zhu V, et al (2014). Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes, 7:415.
5. National Kidney F (2012). KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis, 60(5):850-86.
6. Suleymanlar G, Utas C, Arinsoy T, et al (2011). A population-based survey of Chronic REnal Disease In Turkey--the CREDIT study. Nephrol Dial Transplant, 26(6):1862-71.
7. Gross JL, de Azevedo MJ, Silveiro SP, et al (2005). Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care, 28 (1):164-76.
8. Tripathi YB, Yadav D (2013). Diabetic nephropathy: causes and managements. Recent Pat Endocr Metab Immune Drug Discov, 7(1):57-64.
9. Betonico CC, Titan SM, Correa-Giannella ML, et al (2016). Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control. Clinics (Sao Paulo), 71(1):47-53.
10. Schernthaner G, Schernthaner GH (2013). Diabetic nephropathy: new approaches for improving glycemic control and reducing risk. J Nephrol, 26(6):975-85.
11. Wheeler DC, Becker GJ (2013). Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int, 83(3):377-83.
12. National Kidney F (2007). KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis, 49(2 Suppl 2):S12-154.
13. Shurraw S, Hemmelgarn B, Lin M, et al (2011). Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med, 171(21):1920-7.
14. Zoppini G, Targher G, Chonchol M, et al (2012). Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol, 7(3):401-8.
15. Sonmez A, Haymana C, Bayram F, et al (2018). Turkish nationwide survEy of glycemic and other Metabolic parameters of patients with Diabetes mellitus (TEMD study). Diabetes Res Clin Pract, 146:138-147.
16. Chen R, Ji L, Chen L, et al (2015). Glycemic control rate of T2DM outpatients in China: a multi-center survey. Med Sci Monit, 21:1440-1446.
17. James PA, Oparil S, Carter BL, et al (2014). 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA, 311(5):507-20.
18. Patney V, Whaley-Connell A, et al (2015). Hypertension Management in Diabetic Kidney Disease. Diabetes Spectr, 28(3): 175–180.
19. Lash JP, Go AS, Appel LJ, et al (2009). Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol, 4(8):1302-11.
20. Stevens PE, Schernthaner G, Raptis S, et al (2010). Characteristics, cardiovascular comorbidity and medicines management in patients with type 2 diabetes and CKD: results of the IRIDIEM study. Kidney Blood Press Res, 33(2):119-28.
21. Viazzi F, Greco E, Ceriello A, et al (2018). Apparent Treatment Resistant Hypertension, Blood Pressure Control and the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes. Kidney Blood Press Res, 43(2):422-438.
22. Elnaem MH, Mohamed MHN, Huri HZ, et al (2017). Statin Therapy Prescribing for Patients with Type 2 Diabetes Mellitus: A Review of Current Evidence and Challenges. J Pharm Bioallied Sci, 9(2):80-87.
23. Kim YS, Sunwoo S, Lee HR, et al (2002). Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients. Pharmacoepidemiol Drug Saf, 11(7):593-600.
24. Kiortsis DN, Giral P, Bruckert E, et al (2000). Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther, 25(6):445-51.
Files
IssueVol 50 No 6 (2021) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v50i6.6419
Keywords
Chronic kidney disease Diabetes mellitus Treatment compliance
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Adibelli Z, Duran C. The Compatibility of the Treatment Modalities to the Recommendations of the Kidney Disease Outcomes Quality Initiative Guideline in Chronic Kidney Disease Patients with Diabetes. Iran J Public Health. 2021;50(6):1206-1212.